HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact? HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact?

One of the problems with the new subgroup of HER2 low tumors is that using current assays to measure low levels"is like weighing mice on a scale built for elephants," says one expert.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news